Search

Yanbin Liang

from Irvine, CA
Get Report
Also known as:
Liang Yanbin
Phone and address:
57 Pacific Crst, Irvine, CA 92602
(714) 368-0884
Connected to:
A Liang, 66Abby Liang, 103Alyssa Liang, 28Andy Y Liang, 47Audrey Y Liang, 29Bernice H Liang, 58Billy C Liang, 46Bo Liang, 53Caroline Liang, 31Casey Z Liang, 40

Yanbin Liang Phones & Addresses

  • 57 Pacific Crst, Irvine, CA 92602 (714) 368-0884 (714) 389-9802
  • Corona, CA
  • Eastvale, CA
  • Orange, CA

Work

Company: Maximab/starmab 2018 Position: Founder and chief executive officer

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Indiana University 1996 Specialities: Philosophy, Pharmacology

Skills

Molecular Biology • Assay Development • Biochemistry • Cell • Protein Chemistry • Drug Discovery

Industries

Pharmaceuticals

Resumes

Resumes

Yanbin Liang Photo 1

Founder And Chief Executive Officer

View page
Location:
Irvine, CA
Industry:
Pharmaceuticals
Work:
Maximab/Starmab
Founder and Chief Executive Officer
Allergan 1999 - 2007
Scientist -Senior Scientist -Principal Scientist
Allergan 1999 - 2007
Investigator and Director, Antibody Group Leader and Project Team Leader Darpin Project Team Leader
Eli Lilly and Company 1996 - 1999
Scienitist
Education:
Indiana University 1996
Doctorates, Doctor of Philosophy, Philosophy, Pharmacology
Skills:
Molecular Biology
Assay Development
Biochemistry
Cell
Protein Chemistry
Drug Discovery

Publications

Us Patents

Human Prostaglandin Fp Receptor Variants And Methods Of Using Same

View page
US Patent:
7320871, Jan 22, 2008
Filed:
Jul 14, 2003
Appl. No.:
10/620289
Inventors:
Yanbin Liang - Irvine CA, US
David F. Woodward - Lake Forest CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
C07K 14/705
G01N 33/566
US Classification:
435 72, 435 721, 435 691, 530350
Abstract:
The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25. The invention also provides an isolated polypeptide containing an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 14 and an amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25, or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, or 12. The invention also provides a method for identifying a compound that modulates a FP receptor variant by contacting an isolated FP receptor variant or a FP receptor variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a FP receptor variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the FP receptor variant.

Prostaglandin Epantagonists

View page
US Patent:
7612082, Nov 3, 2009
Filed:
Oct 28, 2004
Appl. No.:
10/976442
Inventors:
Larry A. Wheeler - Irvine CA, US
Michael E. Garst - Newport Beach CA, US
Yanbin Liang - Irvine CA, US
David F. Woodward - Lake Forest CA, US
Achim H.-P. Krauss - San Marcos CA, US
Robert M. Burk - Laguna Beach CA, US
Yariv Donde - Dana Point CA, US
Mark Holoboski - Laguna Niguel CA, US
David W. Old - Irvine CA, US
June Chen - San Juan Capistrano CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 43/42
US Classification:
514284, 514183, 514913
Abstract:
Disclosed herein are methods and compositions related to compound 1 or compound 2.

Recombinant Simian Gpr3 Receptor

View page
US Patent:
20020177190, Nov 28, 2002
Filed:
Sep 18, 2001
Appl. No.:
09/956470
Inventors:
Yanbin Liang - Irvine CA, US
David Woodward - Lake Forest CA, US
Chen Li - Irvine CA, US
International Classification:
C07K014/71
G01N033/53
G01N033/567
C07H021/04
C12P021/02
C12N005/06
US Classification:
435/069100, 435/320100, 435/363000, 530/350000, 435/007210, 536/023500
Abstract:
The invention provides recombinant materials for the production of the simian form of G-protein receptor 3 which differs in several aspects from the human counterpart. Compounds which interact with this receptor are useful in the treatment of glaucoma.

Human Prostaglandin Ep1 Receptor Variants And Methods Of Using Same

View page
US Patent:
20050074847, Apr 7, 2005
Filed:
Oct 7, 2003
Appl. No.:
10/681029
Inventors:
Yanbin Liang - Irvine CA, US
David Woodward - Lake Forest CA, US
International Classification:
C07K014/705
C07H021/04
US Classification:
435069100, 435320100, 435325000, 530350000, 536023500
Abstract:
The present invention relates to nucleic acid molecules encoding novel, alternatively spliced EPreceptor variants. Variant EPpolypeptides and screening methods based on such polypeptides also are provided.

Human Prostaglandin Ep4 Receptor Variants And Methods Of Using Same

View page
US Patent:
20050084929, Apr 21, 2005
Filed:
Oct 17, 2003
Appl. No.:
10/688790
Inventors:
Yanbin Liang - Irvine CA, US
David Woodward - Lake Forest CA, US
International Classification:
C07H021/04
C07K014/71
US Classification:
435069100, 435320100, 435325000, 530350000, 536023500
Abstract:
The present invention provides alternatively spliced EPreceptor variants, as well as related nucleic acid molecules and screening methods.

Human Prostaglandin Dp Receptor Variants And Methods Of Using Same

View page
US Patent:
20050084931, Apr 21, 2005
Filed:
Oct 20, 2003
Appl. No.:
10/689861
Inventors:
Yanbin Liang - Irvine CA, US
David Woodward - Lake Forest CA, US
International Classification:
C07K014/705
C07H021/04
US Classification:
435069100, 435320100, 435325000, 530350000, 536023500
Abstract:
The present invention relates to a nucleic acid molecule encoding a novel, alternatively spliced DP receptor variant. A variant DP polypeptide and screening methods based on such a polypeptide also are provided.

Human Cox-1 Alternatively Spliced Variants And Methods Of Using Same

View page
US Patent:
20050233429, Oct 20, 2005
Filed:
Sep 15, 2003
Appl. No.:
10/663377
Inventors:
Yanbin Liang - Irvine CA, US
David Woodward - Lake Forest CA, US
International Classification:
C12N009/02
C07H021/04
C07K016/40
US Classification:
435189000, 435069100, 435320100, 435325000, 530388260, 536023200
Abstract:
The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22 or 24. The invention also provides an isolated polypeptide containing a) an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 10, and b) an amino acid sequence selected from SEQ ID NOS: 14, 16, 18, 20, 22, or 24; or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8. The invention also provides a method for identifying a compound that modulates a COX-1 variant by contacting an isolated COX-1 variant or a COX-1 variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a COX-1 variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the COX-1 variant.

Treatment Of Dry Age Related Macular Degeneration

View page
US Patent:
20130156766, Jun 20, 2013
Filed:
Nov 15, 2012
Appl. No.:
13/677646
Inventors:
Yanbin Liang - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61K 39/00
A61K 38/17
C07K 16/28
US Classification:
4241351, 4241391, 4241841, 514 208
Abstract:
A method of treating dry age related macular degeneration (“AMD”) comprising administration to the eye of an individual in need thereof of a therapeutically effective amount of an anti-endoglin agent.
Control profile
Yanbin Liang from Irvine, CA Get Report